Northwire Canada EditionFriday, July 24, 2026
Sign inSubscribe
Northwire
⌕
AVX 0.005 −nan% AII 19.91 −1.0% GWM 0.480 +0.0% GEN 0.065 +0.0% NIO 0.135 −3.6% III 7.22 −2.8% NCAU 0.295 −3.3% NEV 0.040 +0.0% ITR 3.00 −1.6% ALDE 2.79 −0.7% TECK 84.18 +4.4% FVI 11.83 −2.2% SUM 1.31 −1.5% RSMX 0.115 +4.5% STW 0.105 +5.0% PAT 0.250 +0.0% AVX 0.005 −nan% AII 19.91 −1.0% GWM 0.480 +0.0% GEN 0.065 +0.0% NIO 0.135 −3.6% III 7.22 −2.8% NCAU 0.295 −3.3% NEV 0.040 +0.0% ITR 3.00 −1.6% ALDE 2.79 −0.7% TECK 84.18 +4.4% FVI 11.83 −2.2% SUM 1.31 −1.5% RSMX 0.115 +4.5% STW 0.105 +5.0% PAT 0.250 +0.0%
Financings

Perimeter closes $2.22M second tranche of offering

By The Northwire Desk — AI Analysis Jul 30, 2025 · 05:33 PINK · 0.245 Perimeter Medical Imaging AI Inc
PINK · Price

Executive Summary

  • Perimeter Medical Imaging AI Inc. has closed the second and final tranche of its prospectus offering, raising approximately $2.25 million in gross proceeds.
  • Total gross proceeds raised under the entire prospectus offering now stand at approximately $5.35 million.
  • The company issued 7,416,667 units at $0.30 per unit, with net proceeds designated for technology commercialization, clinical evidence establishment, product development, and working capital.

Key Details

  • Transaction Structure: Closing of the second tranche of a prospectus offering on a reasonable best effort agency basis.
  • Second Tranche Proceeds: Aggregate gross proceeds of approximately $2,225,000.
  • Total Offering Proceeds: Aggregate gross proceeds of approximately $5,354,840 inclusive of the initial tranche.
  • Units Issued (Second Tranche): 7,416,667 units.
  • Total Units Issued: 17,849,468 units.
  • Price Per Unit: $0.30.
  • Unit Composition: Each unit consists of one common share and one common share purchase warrant.
  • Warrant Terms: Each warrant entitles the holder to acquire one additional common share at an exercise price of $0.35 for a period of 60 months.
  • Agent Commission: The company paid AGP Canada Investments ULC a cash commission equal to 3.5% of the proceeds attributable to non-management subscribers.
  • Use of Proceeds: Commercialization of technology, establishing clinical evidence, continuing product development, working capital, and other general corporate purposes.
  • Related-Party Transaction: Adrian Mendes, an officer of the company, purchased 3,333,334 units. This constituted a related-party transaction under TSX Venture Exchange Policy 5.9 and MI 61-101.
  • Regulatory Exemptions: The company relied on exemptions from formal valuation and minority shareholder approval requirements under MI 61-101 (sections 5.5(a) and 5.7(1)(a)) as the fair market value of the related-party portion did not exceed 25% of the company's market capitalization.
  • Prospectus: Completed by way of a short form prospectus dated May 29, 2025.

Notable Quotes

  • No direct quotes from the CEO/President were included in the provided text.
Read the original news release →

More from Perimeter Medical Imaging AI Inc

Jun 09, 2026 · 09:05

FDA-approved AI surgical imaging pioneer secures minor R&D grant as commercial ramp remains early-stage and cash-burn persists

Other May 28, 2026 · 16:40

Perimeter Medical Imaging AI

Earnings Apr 29, 2026 · 08:00

Perimeter Showcases FDA-Approved Claire System at ASBrS 2026

Other Apr 28, 2026 · 08:15

CEO Insider Commitment Validates FDA Milestone But Dilution Concerns Persist Amidst Consolidation

Financings Apr 21, 2026 · 07:15

Perimeter Medical Imaging AI Secures Lifeline Financing at Discount to Market Price Amidst Cash Burn Concerns

Financings Mar 31, 2026 · 16:15

Perimeter Clears FDA Hurdle and Posts Record Sales, But Cash Runway and Dilution Threaten Near-Term Upside

Earnings